go-v.orgdoi

The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?

Yun Wang, Zhiqiang Wang, Feng-Hua Wang, Yunfei Yuan, Binkui Li, Pei-Rong Ding, Gong Chen, Xiao-Jun Wu, Zhenhai Lu, Zhi-Zhong Pan, De-Sen Wan, Peng Sun, Shumei Yan, Rui‐Hua Xu, Yu-Hong Li · Journal of Cancer · 2017

  • DOI 10.7150/jca.18091
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2017

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2017

Abstract

Peri-operative chemotherapy has been proposed to improve the survival of patients with colorectal cancer hepatic metastases (CRCHM).However, the role of the adjuvant chemotherapy post-metastasectomy for CRCHM patients who have undergone pre-operative chemotherapy is still undetermined.We retrospectively analyzed the role of adjuvant chemotherapy post-metastasectomy on relapse-free survival (RFS) and overall survival (OS) in 163 CRCHM patients who received pre-operative chemotherapy using a Kaplan-Meier curve and univariate/multiple Cox model.Ten patients with rapidly progressing disease were further excluded in a sensitivity analysis.Seven risk factors (metachronous/synchronous metastases, differentiated grade of the primary tumor, number of metastases, size of the max metastasis, duration of pre-operative chemotherapy, radiologic response and pathologic regression) were used to stratify patients and investigate the beneficial features of adjuvant chemotherapy post-metastasectomy.The results indicated that adjuvant chemotherapy post-metastasectomy prolonged both RFS (median RFS: 3.3 vs.

10.2 m, P = 0.002) and OS (median OS: 28.1 vs.

40.7 m, P = 0.005) in CRCHM patients who received pre-operative chemotherapy.After adjusting for other risk factors in a multiple Cox model, the adjuvant chemotherapy group was estimated to have a 54.0 % relapse-free survival (hazard ratio (HR) = 0.46, 95 % confidence interval (CI) 0.31 -0.69, P < 0.001) and a 55.0 % overall survival (HR [95 % CI]: 0.45 [0.26 -0.78], P = 0.005) advantage compared to patients without adjuvant chemotherapy.Additionally, the benefit of adjuvant chemotherapy post-liver resection remained in sensitivity analysis.After the risk stratification, patients with synchronous metastases, poor differentiation, ≥ 3 metastases per patient, size of the maximum metastasis >3 cm, a short duration of pre-operative chemotherapy, radiologic response and poor pathologic regression seem to benefit more from adjuvant chemotherapy.To sum up, adjuvant chemotherapy post-metastasectomy might be considered for CRCHM patients who have received preoperative chemotherapy, especially for those with high-risk factors.

Open the resolved locator · 10.7150/jca.18091

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 12:20 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v08p1179.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.